This study aims to determine the efficacy and tolerability of sibutramine hydrochloride in overweight and obese patients with cardiovascular risk factors. This was a 12-week, open-label, observational trial carried out in primary care settings. Patients' data were obtained from questionnaires received from 153 physicians. A total of 2225 overweight and obese (BMIX27 kg/m 2 ) patients received sibutramine in single daily doses of 10 and/or 15 mg. The study population included patients in general good health and with controlled hypertension (41.2%), type II diabetes mellitus (15.6%), hyperlipidaemia (45.5%), and who were chronic tobacco users (smokers) (37.0%). The main outcome measures were changes in body weight, blood pressure and heart rate, and evaluation of reported adverse events. Reduction of body weight of at least 45% from baseline to week 12 was achieved in 2030 (91%) patients and 410% was achieved in 987 (44%) patients. Baseline differences in the percentages of male and female patients, presence or absence of hyperlipidaemia or smoking status did not appear to affect the rate of weight change. Weight loss was less in patients with type II diabetes mellitus and/or controlled systolic hypertension at baseline compared to those patients without these conditions. Mean systolic and diastolic blood pressure and heart rate decreased from baseline to week 12. Overall, sibutramine was well tolerated. In conclusions, treatment with sibutramine resulted in clinically significant weight loss during short-term therapy in obese adults with a range of cardiovascular risk factors.
Introduction
Hypertension occurs in approximately 60% of patients who are either overweight (body mass index (BMI): 25-29.9 kg/m 2 ) or obese (BMI: X30 kg/m 2 ). 1 The mechanism of the rise in blood pressure associated with an increased body mass has not been determined but insulin resistance, adrenergic activation, pressor effect of leptin, and changes in renal haemodynamics have all been implicated. 2 Obesity further increases total cardiovascular risk due to concomitant dyslipidaemia (in particular, elevated triglycerides and reduced HDL cholesterol levels), diminished glucose tolerance, and left ventricular hypertrophy. 3, 4 These abnormalities related to excess body weight may explain an increased risk of coronary heart disease, congestive heart failure, and ventricular ectopy.
Reversal of obesity induces beneficial changes in cardiovascular risk factors -improved cholesterol and triglyceride levels, reduced left ventricular mass, lower uric acid levels, and improved glucose tolerance. [5] [6] [7] [8] Weight loss can also result in a significant fall in systemic blood pressure and heart rate even when dietary sodium intake is not decreased. 8, 9 For each kilogram of weight loss, blood pressure is reduced by 2.5 mmHg (systolic) and 1.7 mmHg (diastolic), 10 frequently allowing a dose reduction or even withdrawal of antihypertensive drugs.
Sibutramine, a serotonin and norepinephrine reuptake inhibitor, induces weight loss through the dual mechanism of enhancing satiety and attenuating the decrease in resting energy expenditure that occurs with weight loss. 11, 12 Controlled clinical studies have shown that sibutramine produces dose-related weight reduction in obese subjects, as early as 2 weeks after initiation of treatment.
by sibutramine administration could lead to an increase in arterial blood pressure and elevation of heart rate in some patients.
14 When hypertension is well controlled with medication, treatment with sibutramine results in reduced body weight with no adverse effects on blood pressure control. [15] [16] [17] 
Materials and methods

Study design and patient population
This study was carried out in primary care settings from November 2000 through October 2003. Physicians who agreed to participate completed questionnaires that collected information derived from patients who started a 12-week period of sibutramine administration. Male or nonpregnant females who were at least 18 years of age with a BMIX27 kg/m 2 were eligible for inclusion in the study if they were in general good health or were smokers, hyperlipidaemic, or diagnosed with controlled hypertension, and/or type II diabetes mellitus. Patients were diagnosed as hypertensive if their blood pressure was 4140/90 mmHg on two previous visits or if they were using antihypertensive medications. The choice of antihypertensive therapy was at the discretion of the physician. Patients were diagnosed with type II diabetes mellitus if their fasting glucose was 140 mg/dl (7.8 mmol/l) or their 2 h glucose was 200 mg/dl (11.1 mmol/l), according to the 1979 National Diabetes Data Group criteria. 35 Patients were diagnosed with hyperlipidaemia if their total cholesterol was 4240 mg/dl.
Exclusion criteria included uncontrolled (4145/ 90 mmHg) or secondary hypertension, coronary heart disease, congestive heart failure, mental illness, liver or renal failure, thyroid diseases, and history of alcohol or drug addiction. The study Table 1 What is known about obesity and treatment with sibutramine, and what this study adds
What is known on this topic Prevalence of obesity: K Obesity is one of the most visible, yet most neglected, public health problems. 18 It is one of the health disorders (along with tobacco, alcohol, cholesterol, and blood pressure) that contribute to one-third of all disease burden in North America, Europe and the Asian Pacific. 19 K Obesity and its negative health consequences, is so common that it is overtaking traditional public health concerns, such as undernutrition and infectious diseases.
20
K Worldwide, more than 1 billion adults are overweight and at least 300 million are clinically obese. 21 Data suggest that obesity cases in European countries are estimated at 10-20% for men and 10-25% for women. 22 In the last 10 years, obesity cases have increased by about 10-50% in majority of European countries. 23 Effect of weight loss on obesity comorbidities: K Being overweight or obese substantially increases the risk of hypertension, type II diabetes mellitus, CHD, stroke, gallbladder disease, osteoarthritis, sleep apnoea and other respiratory problems, certain types of cancers (endometrial, breast, prostate, and colon).
24
K Modest weight loss from 5 to 10% can result in reduced sickness and death. 25 Overweight patients who lost approximately 5% of their body weight reduced their risk of developing type II diabetes by 58%. 26 Intentional weight reduction of any amount in nonsmoking women, with obesity-related health conditions, ages 40-64 years, reduced the risk of death from all causes by 20% and from diabetes by 30-40%. 27 Modest weight reduction is associated with reductions in blood pressure and cholesterol levels.
28
Sibutramine plus diet and exercise: K Data from controlled clinical trials have shown that sibutramine, when combined with diet and exercise, helps some obese patients lose weight and, more importantly, maintain this weight loss for up to 1 year. 29 K Research showed that: K Sibutramine plus diet and exercise helped three to five times more people lose weight than with diet and exercise alone.
30
K A total of 43% of people using sibutramine plus diet and exercise maintained long-term weight loss, compared to 16% using diet and exercise alone.
31
What this study adds Sibutramine treatment under 'real-life' conditions: K The goal of this large observational study was to document the efficacy, safety and tolerability of sibutramine in treating obesity under 'real-life' practical conditions on patients in Poland with a range of comorbid conditions. It is the first large observational study to generate data on the benefits of weight loss induced by pharmacotherapy in Eastern European patients.
Confirms data regarding metabolic and cardiovascular risk from previous study: K This study confirms data derived from similar obese patients in Germany and concludes that treatment of obese patients with sibutramine even over a relatively short period can significantly impact the patient's metabolic and cardiovascular risk profile.
Scientific validity:
K The large study population increases the scientific validity of this observational study despite the absence of a control group.
Effect of sibutramine on blood pressure: K In contrast with results of controlled clinical trials in which a slight insignificant increase in mean blood pressure was found, 32, 33 or a slight reduction in blood pressure only in the weight-loss responders group was found, 34 in this study, there was a small but significant decline in blood pressure.
Short-term therapy with sibutramine Z Gaciong and G Placha protocol was approved by the Ethics Committee of Warsaw Medical University. Outcome measures were changes in body weight, changes in blood pressure and heart rate, and number of adverse events determined from baseline to Week 12.
A total of 2493 patients received sibutramine at baseline; of these, 2225 (89.2%) completed the study and provided data for all three visits (ie, baseline, Week 4, and Week 12); 28 (1.1%) discontinued treatment due to adverse events; 46 (1.8%) missed at least one visit, and 194 (7.8%) patients returned incomplete or erroneous questionnaires. Patient data were obtained from questionnaires received from 153 physicians. Only the data captured on the questionnaires from the 2225 patients who completed the 12-week study were included in the analysis.
Baseline demographic data are shown in (Table 3) .
Treatment schedule
All patients received general dietary advice regarding weight reduction. After the baseline evaluation, patients received a daily sibutramine dose of 10 or 15 mg. The initial starting dose was determined by the primary physician. Overall, 186 patients (8.3%) were administered sibutramine 15 mg, 1777 patients (79.9%) were administered sibutramine 10 mg, and 262 patients (11.8%) were administered sibutramine 10 mg until Week 4 when the dose was increased to 15 mg. Patients attended follow-up visits after 4 and 12 weeks. At each visit, a medical history was taken, a physical examination was performed, and body weight, height, sitting blood pressure, and heart rate were measured. Incidence of adverse events was also recorded. All other data were obtained from patients' medical records.
Statistical analysis
All tests were two-tailed at a Po0.05 level of significance. Normality of the distributions was checked with the Kolmogorov-Smirnov statistics of the UNIVARIATE procedure of the SAS statistical software package (SAS Institute Inc.). Sequential changes were evaluated by repeated measures ANOVA (SAS GLM procedure), factoring for effects of group, time, and group Â time interaction. Variances were compared by Levene's F test. Multivariate analyses were conducted by stepwise multiple logistic regression, using alpha-criteria for inclusion (ao0.1) or exclusion (a40.1) of an 
Results
Weight loss
The mean change in body weight from baseline to Week 12 was À8.9 kg, corresponding to a 9.6% decrease in body weight. Mean body weight reductions were observed by Week 4, and were accompanied by statistically significant decreases in BMI (Po0.05; Figure 1 ). After 12 weeks of therapy, 91% of patients (2030/2225) had lost X5% of their baseline body weight (5% responders) and 44% of patients (987/2225) had lost X10% of their baseline body weight (10% responders) ( Table 4) . Patients who commenced treatment with 15 mg of sibutramine and continued on that dose throughout the study lost more weight from baseline to Week 12 (À9.3 kg) than those who were started on sibutramine 10 mg (-8.8 kg) and continued on that dose throughout the study; the difference in the percentage change from baseline for these two groups was not significant ( Table 4 ). The percentage of body-weight loss from baseline to Week 12 was similar in males compared to female patients, hyperlipidaemic to normolipidaemic patients, and smokers to nonsmokers. Percentage of weight loss from baseline to Week 12 was significantly less for patients with type II diabetes mellitus (Po0.0001) and controlled hypertension (Po0.05) at baseline compared to patients who were nondiabetic and normotensive at baseline (Table 4 ).
Blood pressure and heart rate
During the 12-week treatment period, mean systolic and diastolic blood pressure decreased significantly in the total study group (Po0.05; Table 5 ); observed mean reductions were greater between baseline and Week 4 than between Week 4 and Week 12. No clinically significant increases in blood pressure were reported during the study. A significant correlation between body-weight loss and reduction of systolic blood pressure was noted (r ¼ 0.11, Po0.0001). These changes in blood pressure were For each category of patients: n for 5% wt loss ¼ 1043, n for 10% wt loss ¼ 987, and n for 5% plus 10% wt loss is 2030. Only those patients who received 10 or 15 mg sibutramine at the first dose and remained on that dose throughout the entire study are presented in order to display the dose response of the drug. wt ¼ weight. *Po0.05, **Po0.003, ***Po0.0001 using Wilcoxon's rank test.
Short-term therapy with sibutramine Z Gaciong and G Placha parallelled by small but statistically significant decreases in mean heart rate (Po0.05; Table 5 ).
Adverse events and reasons for discontinuation
Adverse events were reported by no more than 3.2% of patients. Most adverse events reported were mild to moderate in severity and none were directly attributable to treatment with sibutramine. The most common adverse events are summarized in Table 6 . No serious adverse events were reported and treatment-emergent adverse events resulted in discontinuation of therapy in only 1.1% of patients (28/2493).
Discussion
In this large postmarketing study conducted in Poland, a clinically significant weight loss was observed over the 12-week treatment period with over 91% of patients losing at least 5% of their baseline body weight after 12 weeks of treatment with sibutramine. The weight loss attained in this open-label, observational study was comparable to, and in some cases exceeded, that achieved previously in placebo-controlled studies. 13, 36, 37 Many of the patients in this study had comorbid conditions associated with obesity such as hypertension, type II diabetes mellitus, and dyslipidaemia. The lower percentage weight loss seen especially in patients with diabetic comorbidities at baseline is a well-known phenomenon 38 and related to the fact that diabetic patients, in particular, are on concomitant medications that tend to increase body weight. Hence, the weight loss seen in this subgroup (8.5 vs 9.9% in the nondiabetic subgroup) is both clinically relevant and important, especially considering the short (12 weeks) duration of this study, and exceeded that seen previously over a similar period in double-blind, placebocontrolled studies conducted with sibutramine 15 mg. [39] [40] [41] [42] In contrast to the results of controlled clinical trials in which a slight, insignificant increase in mean blood pressure was found 43, 44 or a slight reduction in blood pressure only in the weight-loss responders group was found, 45 in this study, we recorded a small but significant decline in both systolic and diastolic blood pressure. Heart rate was also significantly reduced. Similar weight and vital sign reductions were also reported in a large postmarketing study performed in Germany. In that study, 6360 obese patients were treated with sibutramine for 12 weeks at 10 and 15 mg doses. Patients lost an average of 10 kg from baseline with 84% able to reduce their weight by at least 5%. The reductions in systolic and diastolic blood pressure were somewhat larger in this German study, probably related to the higher values recorded at baseline in this cohort of patients. 7 The change in heart rate was, however, similar in both observational studies.
The effect of sibutramine in increasing mean blood pressure in some obese and overweight patients has been widely reported 46 and attributed to its effects on sympathetic stimulation. 47 Recent research, however, appears to indicate that the effect of the drug on blood pressure may vary depending on the balance between pre-and post-synaptic adrenergic receptors. This results in both central and peripheral effects on the sympathetic nervous system, resulting in complex and opposing cardiovascular effects following treatment with sibutramine. 48 In subjects with high sympathetic activity, such as obese controlled hypertensives, the central clonidine-like effects on blood pressure predominate. This may explain the significant decrease in blood pressure seen in our study in which 41% of the population at baseline were classified as controlled hypertensives. In normotensive patients and those with controlled hypertension in whom sympathetic activity is normal, sibutramine is likely to have primarily peripheral effects, as noted in the product label.
14 However, in a recent study in obese adolescents treated with sibutramine, similar to our findings, a slight decrease in both blood pressure as well as heart rate was noted. 49 Currently, there is no similar explanation for the small fall in mean heart rate seen in this study. In patients with uncomplicated obesity, treatment with Short-term therapy with sibutramine Z Gaciong and G Placha sibutramine has been reported to be associated with a dose-dependent increase in heart rate with an overall mean increase of 3-7 bpm. 47 However, the authors of a publication that presented the findings from a new metaanalysis of two 12-month sibutramine studies have described a similar small reduction in heart rate in both sibutramine and placebo patients in the subgroups with baseline heart rate X80 bpm. 50 It is interesting to note that the mean baseline heart rate in our study was 79.079.0 bpm.
The current Summary of Product Characteristics (SmPC) 14 does not contraindicate the use of sibutramine in patients with well-controlled hypertension, and several studies conducted over the dose range 10-20 mg for periods of upto 12 months have indicated that sibutramine is safe and effective in these patients. [15] [16] [17] 51 Patients with coronary artery disease, congestive heart failure, tachycardia, peripheral arterial occlusive disease, arrhythmias, and cerebrovascular disease are contraindicated in the SmPC and it also recommends regular monitoring of blood pressure and heart rate in all patients. 14 In conclusion, this study demonstrates that sibutramine treatment safely produced clinically significant weight loss in a primary-care setting for 12 weeks in obese adults who had cardiovascular risk factors. There were small decreases in vital-sign parameters over the study, nevertheless, in clinical practice it is advisable for the physician to closely monitor vital signs in this patient population.
